[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Tomsk National Research Medical Center of the Russian Academy of Sciences\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":419},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,39,69,97,130,153,183,208,232,261,290,319,351,373,395],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100396438","the-study-of-biological-prosthetic-heart-valves-with-the-easy-change-system-100396438",false,"NCT04442100","The Study of Biological Prosthetic Heart Valves With the \"Easy Change\" System","Inclusion Criteria:\n\n1. aortic valve disease requiring surgical disease patients without symptoms with severe aortic stenosis - indexed area of the opening less than 0.5 cm2 \u002F m2, average gradient more than 40 mm RT. Art;\n\n   o patients who require coronary artery bypass grafting with moderate aortic stenosis - indexed area of the hole 0.5 - 1 cm2 \u002F m2, the average gradient is more than 20 mm RT. Art., Regardless of symptoms;patients with symptoms of aortic stenosis, regardless of the severity of stenosis)\n2. mitral valve disease requiring surgical disease\n\nExclusion Criteria:\n\n1. the need for prosthetics of two or more valves\n2. patients with a decrease in LVEF of less than 45%;\n3. the presence of a competing disease or concomitant pathology that significantly affects the prognosis of quality of life or the likelihood of death\n4. high pulmonary hypertension (SDJ above 60 mm Hg. Art.);\n5. the diameter of the ascending aorta is more than 45 mm;\n6. unwillingness of the patient to participate in the study.","ALL","60 Years",{"count":18,"type":19},500,"ESTIMATED","INTERVENTIONAL",[22],"NA","The study of new biological heart valves with the \"easy change\" system, including an assessment of the basic hemodynamic characteristics of the prosthesis, complications associated with valve implantation, and general mortality",[25],"Heart Valve Diseases","RECRUITING","2026-06-25",{"date":29,"type":30},"2026-06-26","ACTUAL",{"date":32,"type":30},"2016-11-29",{"date":34,"type":19},"2026-12-31",{"name":36,"class":37},"Tomsk National Research Medical Center of the Russian Academy of Sciences","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":20,"phases":50,"briefSummary":52,"conditions":53,"keywords":56,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":38},"100500264","phase-4-the-prevalence-of-iron-deficiency-and-the-effectiveness-of-ferinject-in-patients-with-hfpef-id-hfpef-100500264","NCT05793996","The Prevalence of Iron Deficiency and the Effectiveness of Ferinject® in Patients With HFpEF (ID-HFpEF)","Study of the Prevalence of Iron Deficiency Among Hospitalized Patients With HFpEF and the Impact of Ferinject® on Indicators of Quality of Life, Functional Status in Patients With Iron Deficiency","ID-HFpEF","Inclusion Criteria:\n\n* Signed informed consent to participate in the study;\n* In New York Heart Association (NYHA) II-III functional class due to stable symptomatic chronic heart failure (CHF);\n* Left ventricular ejection fraction (LVEF) ≥50%; objective signs of structural and\u002For functional disorders of the heart consistent with the presence of LV diastolic dysfunction\u002Fincreased LV filling pressure, including elevated levels of natriuretic peptide;\n* Screening ferritin below 100 µg\u002FL, or below 300 µg\u002FL when transferrin saturation (TSAT) is below 20%;\n* Screening haemoglobin (Hb) at the time of switching on ( 90-150 g\u002Fl).\n\nExclusion Criteria:\n\n* Uncontrolled arterial hypertension;\n* Аnemia not related to iron deficiency;\n* Аnemia with a hemoglobin level of less than 90 g\u002Fl;\n* Less than 1 year after acute myocardial infarction;\n* Less than 1 year after acute cerebral circulation disorder;\n* Less than 1 year after surgical interventions, including non-cardiac operations and myocardial revascularization (coronary bypass surgery, coronary artery stenting), operations for valvular pathology;\n* Chronic alcoholism (including alcoholic heart disease), mental disorders;\n* Severe hepatic (increased transaminase levels above the upper three limits of normal) and renal insufficiency (glomerular filtration rate less than 15 ml\u002Fmin\u002F1.73 m2);\n* Known active infection, clinically significant bleeding, active malignancy;\n* Severe autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis, etc.);\n* Severe bronchial asthma, COPD in the acute stage;\n* Allergic reactions to medications in the anamnesis, eczema, atopic allergic reaction;\n* Blood transfusions and taking erythropoiesis-stimulating drugs during the previous three months.","18 Years",{"count":49,"type":19},100,[51],"PHASE4","Observational cohort randomized controlled study to study the influence of correction of ID by intravenous injection of ferric carboxymaltose (Ferinject®) on quality of life indicators, functional status in a cohort of patients with HFpEF.",[54,55],"Chronic Heart Failure","Iron Deficiency, Latent",[57,58,59,60],"HFpEF","iron deficiency","ferric carboxymaltose","Ferinject","2026-06-23",{"date":63,"type":30},"2026-06-24",{"date":65,"type":30},"2023-04-28",{"date":67,"type":19},"2026-12",{"name":36,"class":37},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":15,"minAge":47,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":91,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":38},"100465120","pim-incidence-in-older-cardiovascular-patients-during-covid-19-pandemics-100465120","NCT05336565","PIM Incidence in Older Cardiovascular Patients During COVID-19 Pandemics","Incidence of Prescribing Potentially Inappropriate Medications to Older Cardiovascular Patients During COVID-19 Pandemics According to Medical Information System BARS","PIM-BARS","Inclusion Criteria:\n\n* established diagnosis of cardiovascular disease\n* age of 18 years and older\n* enrollment in the reimbursement program in Tomsk Region\n\nExclusion Criteria:\n\n* age of 17 years and younger",{"count":78,"type":19},1000,"OBSERVATIONAL","The aim of the study is to assess the incidence of potentially inappropriate medication (PIM) administration, polypharmacy, and potential drug-drug-interactions (PDDIs) in cardiovascular patients enrolled in the reimbursement program in the time of coronavirus disease (COVID-19) pandemic. Medical information system (MIS) \"BARS\" will be used for inclusion and retrieval of relevant data of cardiovascular patients enrolled in the reimbursement programs in the Tomsk Region. The incidence rates of PIM prescriptions will be assessed in patients aged 75 years and older. Potentially inappropriate medications will be defined according to 2015 Beers criteria. Polypharmacy will be defined as being administered five or more medications at the same time. PDDIs will be checked with Medscape Drug Interaction Checker and rated as 'Contraindicated', 'Serious', and 'Requiring Monitoring'. Combined analysis of retrospective and prospective occurrences of study parameters will be performed. PIM-BARS will evaluate the incidence rates and patterns of PIM prescriptions, polypharmacy, and PDDIs in elderly cardiovascular patients enrolled in the reimbursement program in the time of COVID-19 pandemic.",[82],"Potentially Inappropriate Medications",[84,85,86,87,88,89,90],"Potentially inappropriate medication","Drug-drug-interaction","Polypharmacy","Cardiovascular","Electronic medical record","Medical information system","Prevention",{"date":63,"type":30},{"date":93,"type":30},"2022-07-01",{"date":95,"type":19},"2027-12-31",{"name":36,"class":37},{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":15,"minAge":47,"maxAge":16,"enrollmentInfo":105,"targetDuration":4,"studyType":20,"phases":107,"briefSummary":108,"conditions":109,"keywords":114,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":38},"100644473","comparison-of-focal-cryoablation-vs-radiofrequency-cardioneuroablation-for-bradyarrhythmias-100644473","NCT07671898","Comparison of Focal Cryoablation vs. Radiofrequency Cardioneuroablation for Bradyarrhythmias","Prospective Non-Randomized Comparison of Point-by-Point Cryoablation Using Freezor™ Xtra Versus Radiofrequency Ablation Using TactiFlex™ SE of Parasympathetic Ganglia (Cardioneuroablation) in Patients With Vagally-Mediated Bradyarrhythmias","CRYO-CNA vs RF","Inclusion Criteria:\n\n* Age 18 to 60 years;\n* Symptomatic bradycardia (sinus bradycardia or bradycardia due to atrioventricular block, including transient);\n* Severe asymptomatic sinus bradycardia (heart rate less than 30 beats per minute);\n* Transient second- or third-degree atrioventricular block;\n* Persistent second-degree atrioventricular block;\n* Rhythm pauses greater than 6 seconds;\n* Recurrent syncope or presyncope with documented association with bradycardia (without trauma);\n* Positive response to atropine (heart rate increase ≥25% from baseline or \\>90 beats per minute) OR positive response to exercise (heart rate increase ≥25% from baseline or \\>90 beats per minute, OR conversion of second- or third-degree atrioventricular block to first-degree block or complete normalization of atrioventricular conduction during sinus rhythm);\n\nExclusion Criteria:\n\n* Chronic antiarrhythmic drug therapy (ongoing);\n* Presence of implanted pacemaker, cardiac resynchronization therapy device, or implantable cardioverter-defibrillator;\n* Bradyarrhythmia secondary to medications;\n* Bradyarrhythmia secondary to electrolyte imbalance (hyperkalemia);\n* Bradyarrhythmia secondary to hypothyroidism;\n* Bradyarrhythmia secondary to obstructive sleep apnea syndrome;\n* Absence of response to pharmacological denervation (no heart rate increase after atropine administration up to maximum dose of 0.2 mg\u002Fkg);\n* Clinically significant coronary artery disease;\n* Post-myocardial infarction cardiosclerosis;\n* Hemodynamically significant congenital heart disease (including surgically corrected);\n* Stable ventricular tachycardia in the setting of bradycardia;\n* History of stroke or transient ischemic attack;\n* Prior open-heart surgery;\n* Prior catheter-based coronary artery intervention or percutaneous coronary intervention;\n* Pregnancy or breastfeeding; Age less than 18 years Age greater than 60 years",{"count":106,"type":19},60,[22],"Bradyarrhythmias are conditions where the heart beats too slowly, causing symptoms like dizziness, fainting, and fatigue. In some patients, these slow heart rhythms are caused by overactivity of the vagus nerve (the part of the nervous system that slows the heart down).\n\nCardioneuroablation (CNA) is a catheter-based procedure that targets and reduces the effect of these overactive nerves on the heart. It is an alternative to permanent pacemaker implantation, especially for younger patients.\n\nTraditionally, CNA is performed using radiofrequency (RF) energy to create small burns in specific areas of the heart. This study investigates whether focal cryoablation (freezing technology using the Freezor™ Xtra catheter) is as safe and effective as standard RF ablation for CNA.\n\nThis is a prospective, non-randomized study. Participants will receive either RF ablation (N=30) or cryoablation (N=30). The study will evaluate the recurrence of slow heart rhythms and fainting episodes, as well as any complications, over 12 months of follow-up.",[110,111,112,113],"Bradycardia","Syncope, Vasovagal","Sick Sinus Syndrome","Atrioventricular Block",[115,116,117,118,119,120,121,122,112,113],"Cardioneuroablation,","Cryoablation","Radiofrequency Ablation","Ganglionated Plexi","Parasympathetic Nervous System","Bradyarrhythmias","Functional Bradycardia","Vasovagal Syncope","2026-06-22",{"date":29,"type":30},{"date":126,"type":30},"2024-09-01",{"date":128,"type":19},"2028-12-25",{"name":36,"class":37},{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":15,"minAge":137,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":140,"conditions":141,"keywords":143,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":38},"100535464","registry-of-acute-myocardial-infarction-100535464","NCT06252168","Registry of Acute Myocardial Infarction","RAMI-Tomsk","Inclusion Criteria:\n\n* age of at least 20 years;\n* being a resident or visitor of the city of Tomsk at a time of AMI onset;\n* the presence of definite AMI or possible AMI. Definite AMI is diagnosed in the presence of characteristic ECG changes, regardless of clinical course and changes in serum enzymes; or the presence of typical pain syndrome, \"ambiguous\" ECG changes, and definite increase in the activity of serum enzymes i.e. exceeding the upper limit of normal by 25% or more; or macroscopically detected focus of myocardial necrosis and (or) fresh thrombotic occlusion of the coronary artery. Possible AMI is registered in the presence of typical pain syndrome with ambiguous ECG changes and an ambiguous (up to 25%) increase in the levels of serum enzymes; or the presence of obstruction in the lumen of at least one coronary artery by at least 50% and (or) the presence of a post-infarction scar in the myocardium with a diameter of 0.5 cm or more, while simultaneously excluding a non-coronary cause of death. In case of atypical clinical picture, ambiguous or absent ECG changes, when the enzyme levels are not determined or their activity does not reach a pathological level, AMI case is considered unconfirmed. In the absence of data that could confirm or not confirm AMI, the case is interpreted as \"insufficient data\"\n\nExclusion Criteria:\n\n* none.","20 Years",{"count":139,"type":19},97500,"The Registry of Acute Myocardial Infarction (RAMI) aims at regular and centralized acquiring and processing standard information about verified and suspected cases of acute myocardial infarction (AMI), monitoring of AMI cases, and establishing AMI diagnosis based on standard diagnostic criteria by doctors involved in the registry. The RAMI obtains data from all medical institutions, which could potentially document any cases of suspected AMI.",[142],"Myocardial Infarction, Acute",[144,145],"Acute Myocardial Infarction","Acute Coronary Syndrome","2026-06-19",{"date":63,"type":30},{"date":149,"type":30},"1984-01-01",{"date":151,"type":19},"2050-12-31",{"name":36,"class":37},{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":15,"minAge":47,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":163,"conditions":164,"keywords":167,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":38},"100498445","ultrastructural-characteristics-of-mitochondria-in-cardiomyocytes-in-heart-failure-100498445","NCT05770349","Ultrastructural Characteristics of Mitochondria in Cardiomyocytes in Heart Failure","Association of Ultrastructural Characteristics of Mitochondria in Cardiomyocytes and Signs of Mitochondrial Dysfunction With the Clinical Course and Outcomes of Heart Failure","MITOCH-HF","Inclusion Criteria:\n\n1. The presence of HFrEF or HFmrEF (EF of LV \\\u003C50%)\n2. Obstructive multivessel coronary atherosclerosis as an indication for cardiac surgical correction of coronary blood flow (coronary bypass surgery)\n3. Signed informed consent to participate in the study, separate consents for biomaterial sampling and genetic research\n\nExclusion Criteria:\n\n1. Refusal of revascularization or participation in the study\n2. Additional cardiac surgery other than coronary bypass surgery (valves, aneurysm)\n3. Oncological diseases in the active stage;\n4. The presence of implanted devices (EX, AICD, CT);\n5. Severe renal dysfunction (GFR \\\u003C30 ml\u002Fmin\u002F1.73 m2);\n6. Infiltrative heart diseases (sarcoidosis, amyloidosis, accumulation diseases);\n7. Autoimmune diseases;\n8. Acute infectious and exacerbations of chronic somatic diseases\n9. Type 1 or type 2 diabetes mellitus\n10. Contraindications to myocardial scintigraphy, cardiopulmonary stress test\n11. Impossibility of prescribing optimal drug therapy after cardiac surgery",{"count":162,"type":19},45,"According to modern concepts, mitochondrial dysfunction may be the fundamental basis for the development and progression of CHF, including in patients undergoing myocardial revascularization. The processes of mitochondrial fusion, division and mitophagy are aimed at maintaining cellular homeostasis. A change in the balance of these processes can lead to the accumulation of damaged organelles with impaired functions. In patients with CHF, dysfunctional mitochondria are characterized by size dispersion, crist disorganization, and localization changes relative to myofibrils.\n\nAt the same time, the topic of the influence of mitochondrial dysfunction on the prognosis and clinical course of CHF remains debatable today. Direct study of the structural and functional features of mitochondria in human cardiomyocytes is an extremely difficult task, and therefore, such studies are carried out extremely rarely and on very limited cohorts. In the planned study, due to the long time of the study material recruitment, the ultrastructure of mitochondria in a large cohort of patients, ranging from 45 to 60 people, will be studied.\n\nThe aim of this study is to study the association of mitochondrial dysfunction with the clinical course and outcomes of CHF of ischemic etiology, as well as to assess the degree of compliance of indirect criteria of mitochondrial dysfunction with direct ultrastructural characteristics of mitochondria in cardiomyocytes.\n\nThis single-center prospective cohort study will involve 45-60 patients. The patients will have biopsy samples taken from the right auricle, as well as blood collection and preservation and its derivatives. Electron microscopy of myocardial samples will be performed to assess the ultrastructure of mitochondria of cardiomyocytes. The results of a direct study of mitochondria will be compared with indirect signs of mitochondrial dysfunction: the registration of the phenomenon of increased leaching of radiopharmaceuticals from the myocardium, an increase in the number of copies of mitochondrial DNA and the concentration of cytochrome C in the blood, the affiliation of mitochondrial DNA to haplogroup K. The results obtained in each of the research tasks will have high scientific significance and publication potential.",[165,166],"Heart Failure","Coronary Artery Disease",[168,169,170,171,172,173,174],"Chronic heart failure","Mitochondrial function","Mitochondrial DNA","Electron microscopy","SPECT","Cytochrome C","CABG","2026-03-29",{"date":177,"type":30},"2026-04-02",{"date":179,"type":30},"2023-03-31",{"date":181,"type":19},"2027-11",{"name":36,"class":37},{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":15,"minAge":47,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":193,"conditions":194,"keywords":196,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":38},"100629561","nosocomial-pneumonia-after-coronary-artery-bypass-grafting-100629561","NCT07476274","Nosocomial Pneumonia After Coronary Artery Bypass Grafting","The Impact of Nosocomial Pneumonia on the Outcome and Prognosis of Stable Coronary Artery Disease After Coronary Artery Bypass Grafting","CABG-PNEUM","Inclusion Criteria:\n\n* Age 18 years and older.\n* Myocardial revascularization for CAD via CABG during the current hospitalization, in accordance with the indications defined by the ESC\u002FEACTS Guidelines on Myocardial Revascularization \\[DOI: 10.1093\u002Feurheartj\u002Fehy394\\].\n* Successful transfer from the intensive care unit to a general ward after surgery.\n* One or more of the risk factor for nosocomial pneumonia \\[doi: 10.15829\u002F1560-4071-2024-6094\\].\n* Signed informed consent for participation in the study.\n\nPre-operative Exclusion Criteria:\n\n* Acute coronary syndrome within the last 1 month.\n* Combined surgical intervention for infective endocarditis.\n* Combined valve surgery.\n* Concomitant pulmonary disease requiring respiratory support prior to surgery.\n* Presence of a tracheostomy.\n* Participation in another clinical trial at the time of potential inclusion or within the preceding 3 months.\n* Diagnosis of malignant neoplasms within the last 5 years.\n* Life duration of less than 1 year.\n* HIV infection.\n\nPeri-operative Exclusion Criteria:\n\n* Ventilator-Associated Pneumonia (VAP).\n* Acute Myocardial Infarction after CABG and before inclusion.\n* Acute Stroke after CABG and before inclusion.\n* Pulmonary after CABG and before inclusion.\n* Pulmonary Edema after CABG and before inclusion.\n* Acute Respiratory Distress Syndrome (ARDS) after CABG and before inclusion.\n* Pneumothorax requiring drainage after CABG and before inclusion.\n* Delirium after CABG and before inclusion.\n* Chronic Kidney Disease (CKD) Stage 4-5 \u002F Acute Kidney Injury requiring renal replacement therapy or chronic dialysis.\n* Any perioperative complication requiring the patient's return to the intensive care unit or prolonging the ICU stay beyond 48 hours.\n* Any other active infectious process at a different site.\n* Novel Coronavirus Infection (COVID-19).",{"count":192,"type":19},80,"Observational studies of patients with coronary artery bypass grafting, associated with an unfavorable cardiopulmonary prognosis for at least one year after surgery.\n\nThis is Prospective, cohort, unblinded, observational comparable single center clinical trial. To compare the clinical, laboratory (including complete blood count, metabolic panel, and specific cardiac, inflammatory, infectious, and endothelial biomarkers), functional (ECG, echocardiography, ultrasound, spirometry, cardiopulmonary exercise testing), and radiological (chest X-ray\u002FCT) phenotypes in patients with coronary artery bypass grafting with and without non-ventilator-associated postoperative, nosocomial pneumonia; to identify the factors of early and 1-years cardiopulmonary prognosis.\n\nIncreased risk of cardiovascular outcomes is related with the circulatory arrest, artificial circulation, perioperative trauma and respiratory complications of the postoperative period associating to the different severity and duration of the systemic inflammatory response, immune status disorders, hemostasis disorder, endothelial dysfunction, external respiration dysfunction, anatomic and functional disorders in the heart and lungs. Individual predictors of an unfavorable prognosis can be determined at the stage of before and just after surgery to conduct personalized prevention.\n\nThis study aimed to compare the clinical, laboratory (including complete blood count, metabolic panel, and specific cardiac, inflammatory, infectious, and endothelial biomarkers), functional (ECG, echocardiography, ultrasound, spirometry, cardiopulmonary exercise testing), and radiological (chest X-ray\u002FCT) phenotypes in patients after coronary artery bypass grafting with and without non-ventilator-associated postoperative nosocomial pneumonia; to identify the factors of early and 1-years cardiopulmonary prognosis.",[166,195],"Pneumonia Nosocomial",[197,198,199],"pneumonia","Coronary Artery Bypass Grafting","coronary artery disease","2026-03-18",{"date":202,"type":30},"2026-03-23",{"date":204,"type":30},"2024-10-01",{"date":206,"type":19},"2027-06-30",{"name":36,"class":37},{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":218,"conditions":219,"keywords":221,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":38},"100629918","risk-stratification-of-mace-in-heart-failure-patients-who-undergoing-cabg-100629918","NCT07480915","Risk Stratification of MACE in Heart Failure Patients Who Undergoing CABG","Risk Stratification of MACE Based on GDF-15 in Heart Failure Patients Who Undergoing Coronary Artery Bypass Grafting: an Observational Multicenter Prospective Study","PROFILE-HF","Inclusion Criteria:\n\n* Heart Failure\n* Planned coronary artery bypass grafting\n\nExclusion Criteria:\n\n* Myocardial infarction\n* Stroke\n* Presence of implanted devices;\n* Need for additional cardiac surgery other than coronary artery bypass grafting (valve repair, aneurysm);\n* Severe renal dysfunction (GFR \\\u003C30 ml\u002Fmin\u002F1.73 m2);\n* Severe comorbidities: active cancer; infiltrative cardiac diseases (sarcoidosis, amyloidosis, storage diseases); autoimmune diseases; acute infectious diseases and exacerbations of chronic somatic diseases.",{"count":217,"type":19},160,"PROFILE-HF is a multicenter, observational, prospective study of the clinical course and outcomes of chronic heart failure (HF) and coronary artery disease (CAD) in patients undergoing coronary artery bypass grafting (CABG).\n\nThe objective of the study is to develop a method for assessing the risk of adverse cardiovascular events in patients with CAD and HF who have undergone CABG, based on preoperative GDF-15 concentrations.\n\nThe study will have a 12-month follow-up period; one in-person visit is planned at the end of the follow-up period. If it is not possible to visit a doctor in person, information will be collected through telephone contact with the patient or his relative or person caring for the patient.",[165,220,174],"CAD - Coronary Artery Disease",[165,166,174,198,222,223,224],"GDF-15","Growth differentiation factor - 15","Prognosis","2026-03-13",{"date":200,"type":30},{"date":228,"type":30},"2026-03-04",{"date":230,"type":19},"2028-03",{"name":36,"class":37},{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":239,"sex":15,"minAge":47,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":242,"conditions":243,"keywords":248,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":38},"100528356","telecommunication-technology-based-online-survey-100528356","NCT06159699","Telecommunication Technology-based Online Survey","New Challenges for the Population on the Path to Achieving Active Longevity: an Online Survey of Respondents Using Telecommunication Technologies","Inclusion Criteria:\n\n* age of 18 years and older\n* signing the informed concent form online\n* completion of the entire questionnaire\n\nExclusion Criteria:\n\n* age under 18 years\n* refuse to sign the informed concent form",true,{"count":241,"type":19},2000,"The aim of this study is to identify and assess new health-associated risk factors, including clinical-pharmacological risk factors. The cohort is built using telecommunication approaches. The associations between clinical-pharmacological, social, demographic, behavioral, and environmental characteristics will be assessed. The continuous depersonalized online survey is performed using the original informational resources in the form of specially designed web-site aimed at identification and assessment of population-based pharmacotherapy patterns including characteristics of self-medication, biologically active food supplement intake, polypharmacy, and adverse drug-drug interactions in the people residing in the ecological conditions of various regions of the country. The invitations to participate in the online survey are sent via the SMS messages using the SMS-Target tool provided by OOO T2 Mobile Company. The survey is performed online at www.zdorov.tpu.ru and www.zdorov.expert both specifically designed for questionnaire publication and data accumulation.",[244,86,245,246,247],"Risk Factors","Drug Interactions","Self Medication","COVID-19",[86,249,246,247,250,251,252],"Potential Drug-Drug Interactions","Medical Imaging","Environmental Risk Factors","Protracted Low-Dose-Rate Radiation Exposure","2026-01-23",{"date":255,"type":30},"2026-01-27",{"date":257,"type":30},"2022-12-02",{"date":259,"type":19},"2028-12-31",{"name":36,"class":37},{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":15,"minAge":47,"maxAge":268,"enrollmentInfo":269,"targetDuration":4,"studyType":20,"phases":270,"briefSummary":271,"conditions":272,"keywords":277,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":289,"locationsCount":38},"100559677","intracoronary-hypothermia-as-a-prevention-of-reperfusion-injury-in-myocardial-infarction-100559677","NCT06567249","Intracoronary Hypothermia as a Prevention of Reperfusion Injury in Myocardial Infarction.","Selective Intracoronary Hypothermia as a Prevention of Reperfusion Injury in ST-elevation Myocardial Infarction.","Inclusion Criteria:\n\n* Acute ST-elevation myocardial infarction\n* Time from onset of symptoms less than 12 hours\n* Given informed consent\n\nExclusion Criteria:\n\n* Contraindication to MRI\n* Cardiogenic shock\n* Conduction disturbance: Atrioventricular block: 2nd and 3rd degree. SA block.\n* Sick sinus syndrome requiring implantable pacemaker\n* Pulmonary edema\n* Active inflammatory condition\n* Active chemo\u002Fradiation therapy","90 Years",{"count":106,"type":19},[22],"Acute myocardial infarction with ST segment elevation is often accompanied by a totally occluded coronary artery. Which has deleterious effects on heart muscle. Primary percutaneous coronary intervention is the most effective mode of treatment for ST-elevation myocardial infarction (STEMI) patients. Despite the restoration of the blood flow, 30-60% of patients develop microvascular obstruction, which lowers the effects of the coronary blood flow restoration. The most advanced coronary microvascular obstruction presents as a no-reflow phenomenon, which is an abrupt deceleration or absence of coronary flow following stent implantation. Several pharmacological treatments have been proposed, as well as deferred stenting, but none of them really helped. Thus, new ways of alleviating coronary obstruction are warranted. One of the new ways of mitigating the reperfusion injury is intracoronary hypothermia, which showed to be safe on a handful of patients in small series. In the animal studies, intracoronary hypothermia demonstrated a protective effect in terms of reducing infarct area. But clinical studies failed to reproduce the protective effects of intracoronary hypothermia. Thus, our study, using a modified hypothermia protocol, will test the hypothermia hypothesis.",[273,274,275,276],"Myocardial Infarction","ST-Elevation Myocardial Infarction (STEMI)","Reperfusion Injury","Microvascular Occlusion",[278,279,280,281,282],"hypothermia","ST-elevation myocardial infarction","microvascular obstruction","reperfusion injury","STEMI","2025-12-08",{"date":285,"type":30},"2025-12-16",{"date":287,"type":30},"2024-05-05",{"date":67,"type":19},{"name":36,"class":37},{"id":291,"slug":292,"hasResults":11,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":296,"eligibilityCriteria":297,"healthyVolunteers":239,"sex":15,"minAge":47,"maxAge":298,"enrollmentInfo":299,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":301,"conditions":302,"keywords":306,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":38},"100590602","mechanical-dyssynchrony-and-microvascular-dysfunction-by-spect-100590602","NCT06969547","Mechanical Dyssynchrony and Microvascular Dysfunction by SPECT","Evaluation the Capabilities of Cardiac Mechanical Dyssynchrony in the Diagnosis of Myocardial Microvascular Dysfunction in Chronic Ischemic Heart Disease","MD&MD","Inclusion Criteria:\n\n* Ischemia with no obstructive coronary arteries (INOCA)\n* Obstructive coronary artery disease (CAD)\n* Patients without evidence of coronary heart disease\n\nExclusion Criteria:\n\n* Left ventricular ejection fraction \\\u003C55% according to echocardiography;\n* History of myocardial infarction\u002Frevascularization;\n* hypertension: systolic blood pressure \\>180 mm Hg. Art., diastolic BP\\>110 mm Hg. Art.;\n* systolic arterial hypotension \\\u003C80 mm Hg. Art.;\n* atrial fibrillation;\n* AV blockade of the III degree; sick sinus syndrome;\n* massive pulmonary embolism (PE) with a high degree of pulmonary hypertension;\n* the presence of significant valvular pathology (mitral insufficiency ≥ 3 degrees, aortic insufficiency ≥ 3 degrees, tricuspid regurgitation ≥ 3 degrees).\n* severe course of bronchial asthma, chronic obstructive pulmonary disease;\n* decompensated type 2 diabetes,\n* severe liver or kidney failure (glomerular filtration rate \\\u003C50 ml\u002Fmin\u002F1.73 m3 (CKD-EPI),\n* morbid obesity (body mass index \\>45);\n* history of myocarditis\n* indications of poor drug tolerance;\n* oncological diseases;\n* chronic alcoholism, mental disorders;\n* other severe comorbidity,\n* refusal to participate in the study.","75 Years",{"count":300,"type":19},75,"The project is aimed at studying the feasibility of mechanical dyssynchrony of the left ventricle of the heart, determined by SPECT (gated MPI), as well as its stress-induced dynamics, in the evaluation of patients with coronary microvascular dysfunction in chronic coronary heart diseasу.",[303,304,305],"Myocardial Blood Flow Reserve","Mechanical Dyssynchrony","Coronary Arterial Disease (CAD)",[172,307,308,309,310],"gated MPI","mechanical dyssynchrony","dobutamine","myocardial bloow flow reserve","2025-09-22",{"date":313,"type":30},"2025-09-24",{"date":315,"type":30},"2023-10-01",{"date":317,"type":19},"2026-05-15",{"name":36,"class":37},{"id":320,"slug":321,"hasResults":11,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":325,"eligibilityCriteria":326,"healthyVolunteers":11,"sex":15,"minAge":47,"maxAge":327,"enrollmentInfo":328,"targetDuration":4,"studyType":20,"phases":329,"briefSummary":330,"conditions":331,"keywords":338,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":348,"leadSponsor":350,"locationsCount":38},"100498344","conventional-biventricular-versus-left-bundle-branch-pacing-on-outcomes-in-heart-failure-patients-100498344","NCT05769036","Conventional Biventricular Versus Left Bundle Branch Pacing on Outcomes in Heart Failure Patients","Randomized Study of Integrated Evaluation of Conventional Biventricular and Left Bundle Branch Pacing Therapy Effect on Left Ventricular Remodeling and Clinical Outcomes in Patients With Chronic Heart Failure With Reduced Ejection Fraction","RECOVER-HF","Inclusion criteria:\n\n1. The patient is willing and able to comply with the protocol and has provided written informed consent;\n2. Male or female patients aged 18 to 80 years;\n3. Patients with ischemic or non-ischemic cardiomyopathy;\n4. Symptomatic HF for at least 3 months prior to enrollment in the study;\n5. New York Heart Association (NYHA) functional class HF ≥ II;\n6. Patients with HF in sinus rhythm (SR) with LVEF ≤ 35% (measured in the last 6 weeks prior to enrollment), QRS duration ≥150 ms with LBBB morphology;\n7. Patients with HF in SR with LVEF ≤ 35% (measured in the last 6 weeks prior to enrollment), QRS duration 130-149 ms with LBBB morphology;\n8. Patients with HF in SR with LVEF ≤ 35% (measured in the last 6 weeks prior to enrollment), QRS duration ≥150 ms with non-LBBB morphology;\n9. Patients with symptomatic persistent or permanent atrial fibrillation, HF with LVEF \\\u003C 40% (measured in the last 6 weeks prior to enrollment) and an uncontrolled heart rate who are candidates for atrioventricular junction ablation (irrespective of QRS duration);\n10. Patients with HF, LVEF \\\u003C 40% (measured in the last 6 weeks prior to enrollment) and indications for continuous ventricular pacing due to bradycardia;\n11. Patients who have received a conventional pacemaker or an implanted cardioverter-defibrillator and who subsequently develop symptomatic HF with LVEF \\\u003C 40% (measured in the last 6 weeks prior to enrollment) despite optimal medical therapy, and who have a significant proportion of right ventricle pacing;\n12. Optimal HF medical therapy.\n\nExclusion criteria:\n\n1. Coronary artery (CA) bypass grafting, balloon dilatation or CA stenting within 3 months prior to enrollment;\n2. Acute myocardial infarction within 3 months prior to enrollment;\n3. Acute coronary syndrome;\n4. Patients with planned cardiovascular intervention (CA bypass grafting, balloon dilatation or CA stenting);\n5. Patients listed for heart transplant;\n6. Patients with implanted cardiac assist device;\n7. Acute myocarditis;\n8. Infiltrative myocardial disease;\n9. Hypertrophic cardiomyopathy;\n10. Severe primary stenosis or regurgitation of the mitral, tricuspid and aortic valves;\n11. Woman currently pregnant or breastfeeding or not using reliable contraceptive measures during fertility age;\n12. Mental or physical inability to participate in the study;\n13. Patients unable or unwilling to cooperate within the study protocol;\n14. Patients with rheumatic heart disease;\n15. Mechanic tricuspid valve patients;\n16. Patients with any serious medical condition that could interfere with this study;\n17. Enrollment in another investigational drug or device study;\n18. Patients not available for follow-up;\n19. Patients with severe chronic kidney disease (estimated glomerular filtration rate ˂ 30 ml\u002Fmin\u002F1.73 m2);\n20. Life expectancy ≤ 12 months;\n21. Participation in another telemonitoring concept.","80 Years",{"count":106,"type":19},[22],"Heart failure (HF) is the most common nosology encountered in clinical practice. Its incidence and prevalence increase exponentially with increasing age and it is associated with increased mortality, more frequent hospitalization and decreased quality of life. An initial approach to the treatment of HF patients with reduced left ventricular (LV) systolic function and left bundle branch block (LBBB) was implantation of cardioresynchronization device using biventricular pacing. This has resulted in long-term clinical benefits such as improved quality of life, increased functional capacity, reduced HF hospitalizations and overall mortality. However, conventional cardiac resynchronization therapy (CRT) is effective in only 70% of patients. And the remaining 30% of patients are non-responders to conventional CRT. Subsequently, His bundle pacing (HBP) has been developed to achieve the same results. According to other studies HBP has showed greater improvement in hemodynamic parameters than with conventional biventricular CRT. But, nevertheless, there are significant clinical troubles with HBP. In this regard, in 2017, the left bundle branch pacing (LBBP) was developed, which demonstrated clinical advantages compared to biventricular CRT. This method has become an alternative to HBP due to the stimulation of LBB outside the blocking site, a stable pacing threshold and a narrow QRS duration. A series of case reports and observational studies have demonstrated the efficacy and safety of LBBP in patients with CRT indications. However, it is not enough data about CRT with LBBP effectiveness in LV remodeling, reducing mortality and complications. According to our hypothesis, CRT with LBBP compared with conventional biventricular CRT will significantly improve the clinical outcomes and reverse LV remodeling in patients with chronic HF with reduced LV ejection fraction and reduce the number of non-responders to conventional CRT.",[165,332,333,334,335,336,337],"Left Bundle-Branch Block","Ischemic Cardiomyopathy","Non-ischemic Dilated Cardiomyopathy","Left Ventricular Dysfunction","Left Ventricular Dyssynchrony","Left Ventricle Remodeling",[339,340,341,342,343],"Cardiac Resynchronization Therapy","Biventricular Pacing","Left Bundle Branch Pacing","Speckle Tracking Echocardiography","Biomarker of Fibrosis and Remodeling","2025-09-03",{"date":346,"type":30},"2025-09-10",{"date":315,"type":30},{"date":349,"type":19},"2028-09-01",{"name":36,"class":37},{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":11,"sex":15,"minAge":47,"maxAge":4,"enrollmentInfo":358,"targetDuration":4,"studyType":20,"phases":360,"briefSummary":361,"conditions":362,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":38},"100529176","high-dose-inhalations-of-nitric-oxide-in-the-treatment-of-pneumonia-100529176","NCT06170372","High-dose Inhalations of Nitric Oxide in the Treatment of Pneumonia","The Effectiveness of Adding Multiple Intermittent High-dose Inhalations of Nitric Oxide to Standard Antibacterial Therapy in the Treatment of Pneumonia","Inclusion Criteria:\n\n1. An established diagnosis of Nosocomial Pneumonia (NP) after cardiac surgery under cardiopulmonary bypass (CPB) or hospitalization for Community-acquired pneumonia (CAP).\n2. Spontaneous breathing.\n3. Age \\> 18 years.\n4. Signed informed consent.\n5. Negative result of immunochromatographic Severe acute respiratory syndrome-related coronavirus 2 rapid antigen test on the day of diagnosis of pneumonia.\n\nDiagnostic criteria for NP The diagnosis of NP is considered established when the number of points on the\n\nClinical Pulmonary Infection Score (CPIS) is greater than 6:\n\nDiagnostic criteria for CAP:\n\nRadiologically confirmed focal pulmonary opacity and at least 2 clinical symptoms and signs of the following:\n\n1. acute fever at the onset of the disease (t° \\> 38.0°C);\n2. cough with sputum;\n3. physical signs (crepitus\u002Ffine rales, bronchial breathing, shortening of percussion sound);\n4. leukocytosis \\> 10x109\u002Fl and\u002For left shift (\\> 10%)\n\nExclusion Criteria:\n\n1. Diagnosed infectious process of another localization (surgical site infection (SSI), acute and chronic urinary tract infection (active), catheter-related bloodstream infection, peritonitis, infective endocarditis etc.).\n2. Mechanical ventilation\n3. Presence of tracheostomy\n4. Patient's participation in another clinical trial at the time of screening or within the previous 3 months.\n5. Concomitant pulmonary disease with the need for respiratory support before the development of pneumonia.\n6. History of malignancy or other irreversible diseases\u002Fconditions with a life expectancy of less than 1 year.\n7. Presence of HIV infection",{"count":359,"type":19},200,[22],"This is a multicenter, prospective randomized controlled trial. At least 2 but no more than 5 centers are expected to participate in the study.\n\nThe primary objective is to test the hypothesis that the addition of high-dose inhaled nitric oxide therapy to standard treatment has a positive effect on the clinical course of pneumonia and the structure and function of cardiopulmonary system.\n\nNumber of participants: 200, including the subproject NO-PNEUMONIA-CAP - 100 CAP participants, the subproject NO-PNEUMONIA-NP - 100 NP participants.\n\nNumber of groups: 4 Inhalation of iNO at a dose of 200 ppm for 30 minutes under the control of methemoglobin level (no more than 5%) three times a day if the patient is allocated to the main group. The general course of iNO therapy will last until the pneumonia resolves, but no more than 7 days. Recording of vital signs and safety assessment will be carried out immediately before the initiation of NO therapy and every 15 minutes after its start (pulse, blood pressure, respiratory rate, SpO2, temperature, MetHb level).",[363,364],"Nosocomial Pneumonia","Community-acquired Pneumonia","2025-04-07",{"date":367,"type":30},"2025-04-10",{"date":369,"type":30},"2024-01-15",{"date":371,"type":19},"2027-01-15",{"name":36,"class":37},{"id":374,"slug":375,"hasResults":11,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":4,"eligibilityCriteria":379,"healthyVolunteers":239,"sex":15,"minAge":380,"maxAge":298,"enrollmentInfo":381,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":382,"conditions":383,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":394},"100391098","study-of-treatment-of-thoracic-aortic-aneurysms-and-dilatation-in-combination-with-tricuspid-and-bicuspid-aortic-valves-100391098","NCT04372563","Study of Treatment of Thoracic Aortic Aneurysms and Dilatation in Combination With Tricuspid and Bicuspid Aortic Valves.","Clinical Study of Diagnosis and Treatment of Thoracic Aortic Aneurysms and Dilatation in Combination With Tricuspid and Bicuspid Aortic Valves.","Inclusion Criteria:\n\n1. Extension of the ascending aorta less than 55 mm\n2. Tricuspid Aortic Valves.\n3. Extension of the ascending aorta more than 45 mm\n\nExclusion Criteria:\n\n1. Age less 45 years\n2. Age more 75 years\n3. Multiple organ failure\n4. oncological disease","45 Years",{"count":192,"type":19},"Clarification of indications for surgical correction in patients with borderline expansion of the ascending aorta",[384,385],"Ascending Aorta Aneurysm","Dilation of the Ascending Aorta","2024-11-21",{"date":388,"type":30},"2024-11-25",{"date":390,"type":30},"2020-01-24",{"date":392,"type":19},"2026-01-24",{"name":36,"class":37},2,{"id":396,"slug":397,"hasResults":11,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":401,"eligibilityCriteria":402,"healthyVolunteers":11,"sex":15,"minAge":47,"maxAge":327,"enrollmentInfo":403,"targetDuration":4,"studyType":20,"phases":405,"briefSummary":406,"conditions":407,"keywords":408,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":412,"lastUpdatePostDateStruct":413,"startDateStruct":415,"completionDateStruct":417,"leadSponsor":418,"locationsCount":38},"100497721","left-bundle-branch-pacing-on-outcomes-and-ventricular-remodeling-in-biventricular-crt-nonresponders-100497721","NCT05760924","Left Bundle Branch Pacing on Outcomes and Ventricular Remodeling in Biventricular CRT Nonresponders","Randomized Trial of Left Bundle Branch Pacing Effect on Clinical Outcomes and Left Ventricular Remodeling in Patients With Nonresponse to Biventricular Cardiac Resynchronization Therapy","RESCUE","Inclusion criteria:\n\n1. The patient is willing and able to comply with the protocol and has provided written informed consent;\n2. Male or female patients aged 18 to 80 years;\n3. Patients with ischemic or non-ischemic cardiomyopathy;\n4. Symptomatic HF for at least 3 months prior to enrollment in the study;\n5. New York Heart Association (NYHA) functional class HF ≥ II;\n6. Patients who are non-responders to biventricular CRT with HF, reduced LVEF and CRT-D replacement or one of the CRT-D leads replacement indications (without LVEF increase ≥ 5% and\u002For without a left ventricle end-systolic volume decrease ≥ 15% after CRT-D implantation at least 1 year old);\n7. Optimal HF medical therapy.\n\nExclusion criteria:\n\n1. Coronary artery (CA) bypass grafting, balloon dilatation or CA stenting within 3 months prior to enrollment;\n2. Acute myocardial infarction within 3 months prior to enrollment;\n3. Acute coronary syndrome;\n4. Patients with planned cardiovascular intervention (CA bypass grafting, balloon dilatation or CA stenting);\n5. Patients listed for heart transplant;\n6. Patients with implanted cardiac assist device;\n7. Acute myocarditis;\n8. Infiltrative myocardial disease;\n9. Hypertrophic cardiomyopathy;\n10. Severe primary stenosis or regurgitation of the mitral, tricuspid and aortic valves;\n11. Woman currently pregnant or breastfeeding or not using reliable contraceptive measures during fertility age;\n12. Mental or physical inability to participate in the study;\n13. Patients unable or unwilling to cooperate within the study protocol;\n14. Patients with rheumatic heart disease;\n15. Mechanic tricuspid valve patients;\n16. Patients with any serious medical condition that could interfere with this study;\n17. Enrollment in another investigational drug or device study;\n18. Patients not available for follow-up;\n19. Patients with severe chronic kidney disease (estimated glomerular filtration rate ˂ 30 ml\u002Fmin\u002F1.73 m2);\n20. Life expectancy ≤ 12 months;\n21. Participation in another telemonitoring concept.",{"count":404,"type":19},30,[22],"Heart failure (HF) is the most common nosology encountered in clinical practice. Its incidence and prevalence increase exponentially with increasing age and it is associated with the increased mortality, more frequent hospitalization and decreased quality of life. An initial approach to the treatment of HF patients with reduced left ventricular (LV) systolic function and left bundle branch block (LBBB) was implantation of device for cardiac resynchronization therapy using biventricular pacing. This has resulted in long-term clinical benefits such as improved quality of life, increased functional capacity, reduced HF hospitalizations and overall mortality. However, conventional cardiac resynchronization therapy (CRT) is effective in only 70% of patients. And the remaining 30% of patients are non-responders to conventional CRT. Cardiac conduction system pacing is currently a promising technique for these patients. Particularly, His bundle pacing (HBP) has been developed to achieve the same results. According to other studies HBP has shown greater improvement in hemodynamic parameters comparing with conventional biventricular CRT. But, nevertheless, there are significant clinical troubles with HBP, especially high pacing threshold. In this regard, in 2017, the left bundle branch pacing (LBBP) was developed, which demonstrated clinical advantages compared to conventional biventricular CRT. Also, since 2019, left bundle branch pacing-optimized CRT (LBBPO CRT) has been used in clinical practice. These methods have become an alternative to HBP due to the stimulation of LBB outside the blocking site, a stable pacing threshold and a narrow QRS complex duration on electrocardiogram. A series of case reports and observational studies have demonstrated the efficacy and safety of LBBP and LBBPO CRT in patients with CRT indications. However, it is not enough data about impact of CRT with LBBP and combined CRT with LBBP and LV pacing on myocardial remodeling, reducing mortality and complications. According to our hypothesis, CRT with LBBP and combined CRT with LBBP and LV pacing compared with conventional biventricular pacing will significantly improve the clinical outcomes and reverse myocardial remodeling in patients who are non-responders to biventricular CRT with HF, reduced LV ejection fraction and with indications to CRT devices with defibrillator function (CRT-D) or one of the CRT-D leads replacement.",[165,332,333,334,335,337],[339,340,341,342,343,409,410,411],"Combined Left Bundle Branch and Left Ventricular Pacing","CRT Non-responder","CRT Responder","2024-11-20",{"date":414,"type":30},"2024-11-22",{"date":416,"type":30},"2024-11-01",{"date":349,"type":19},{"name":36,"class":37},""]